Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![$orkas Graphic](https://lunarcrush.com/gi/w:26/t:$orkas.png) $orkas

Oruka Therapeutics, Inc. (ORKA) sees positive developments as the FDA clears its IND application for Phase 2a trial of ORKA-001. Analysts are reiterating Buy ratings with price targets reflecting the positive developments.

### About $orkas
Oruka Therapeutics, Inc. (ORKA) is a company focused on therapeutics.  

### Engagements: XX [#](/topic/$orkas/interactions)
---
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$orkas/c:line/m:interactions.svg)  
[Engagements 24-Hour Chart Data](/topic/$orkas/time-series/interactions.tsv)  
**Current Value**: XX  
**Daily Average**: XXX  
**1-Year High**: XXXXX on 2025-07-23  
**1-Year Low**: X on 2025-07-06  

| Social Network | X  |
| -------------- | -  |
| Engagements    | XX |
  

  
  
### Mentions: X [#](/topic/$orkas/posts_active)
---
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$orkas/c:line/m:posts_active.svg)  
[Mentions 24-Hour Chart Data](/topic/$orkas/time-series/posts_active.tsv)  
**Current Value**: X  
**Daily Average**: X  
**1-Year High**: X on 2025-07-21  
**1-Year Low**: X on 2025-05-22  

| Social Network | X |
| -------------- | - |
| Mentions       | X |
  

  
  
### Creators: X [#](/topic/$orkas/contributors_active)
---
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$orkas/c:line/m:contributors_active.svg)  
[Creators 24-Hour Chart Data](/topic/$orkas/time-series/contributors_active.tsv)  
X unique social accounts have posts mentioning $orkas in the last XX hours which is no change from in the previous XX hours
**Daily Average**: X  
**1-Year High**: X on 2025-05-22  
**1-Year Low**: X on 2025-05-22  

The most influential creators that mention $orkas in the last XX hours

| Creator                                    | Rank | Followers | Posts | Engagements |
| -------                                    | ---- | --------- | ----- | ----------- |
| [@Quantumup1](/creator/twitter/Quantumup1) | X    | XXXXX     | X     | XXX         |

[View More](/list/creators/$orkas/100)

**Top assets mentioned**
In the posts about $orkas in the last XX hours

[Johnson & Johnson (JNJ)](/topic/$jnj)
[Oruka Therapeutics, Inc. Common Stock (ORKA)](/topic/$orka)
[AbbVie Inc (ABBV)](/topic/$abbv)

**Top topics mentioned**
In the posts about $orkas in the last XX hours

[$ucbjy](/topic/$ucbjy), [$jnj](/topic/$jnj), [$orka](/topic/$orka), [$abbv](/topic/$abbv), [hc](/topic/hc)

### Top Social Posts [#](/topic/$orkas/posts)
---
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"H.C. Wainwright reit'd $ORKA Buy/$45 after Oruka📰that the FDA had cleared its IND application for its Phase 2a trial of ORKA-001 (the company's long-acting anti-IL-23p19 antibody) in moderate-to-severe PsO called EVERLAST-A. $ABBV $PTGX - $JNJ #EDAV25 H.C. Wainwright said in its note: "This program is a randomized double-blind placebo-controlled Phase 2a trial designed to evaluate the safety and efficacy of a single dose level of ORKA-001 in moderate-to-severe psoriasis patients. EVERLAST-A will enroll approximately XX patients randomized 3:1 to receive ORKA-001 or matching placebo. The"  
[@Quantumup1](/creator/x/Quantumup1) on [X](/post/tweet/1948085842020590074) 2025-07-23 18:20:33 UTC 3529 followers, 1203 engagements


"Stifel reiterated $ORKA Buy-$47 after $ORKA's disclosure of the IND clearance for ORKA-001 and then catching up w/ mgmt. $ABBV $PTGX $JNJ #EADV25 $UCBJY $MLTX Stifel said in its note: "We caught up with management who noted that the IND clearance was based on interim Ph1 data (safety/tolerability) and Ph2a sites are open and actively enrolling -- Ph1 results to be presented at #EADV in September. Recall ORKA-001 is a next-gen IL-23p19 which is designed to explore greater exposure and improved dosing vs. mega-blockbuster Skyrizi based on exploratory IST results in Psoriasis demonstrating"  
[@Quantumup1](/creator/x/Quantumup1) on [X](/post/tweet/1947283589118198123) 2025-07-21 13:12:41 UTC 3530 followers, 4206 engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

$orkas Graphic $orkas

Oruka Therapeutics, Inc. (ORKA) sees positive developments as the FDA clears its IND application for Phase 2a trial of ORKA-001. Analysts are reiterating Buy ratings with price targets reflecting the positive developments.

About $orkas

Oruka Therapeutics, Inc. (ORKA) is a company focused on therapeutics.

Engagements: XX #


Engagements Line Chart
Engagements 24-Hour Chart Data
Current Value: XX
Daily Average: XXX
1-Year High: XXXXX on 2025-07-23
1-Year Low: X on 2025-07-06

Social Network X
Engagements XX

Mentions: X #


Mentions Line Chart
Mentions 24-Hour Chart Data
Current Value: X
Daily Average: X
1-Year High: X on 2025-07-21
1-Year Low: X on 2025-05-22

Social Network X
Mentions X

Creators: X #


Creators Line Chart
Creators 24-Hour Chart Data
X unique social accounts have posts mentioning $orkas in the last XX hours which is no change from in the previous XX hours Daily Average: X
1-Year High: X on 2025-05-22
1-Year Low: X on 2025-05-22

The most influential creators that mention $orkas in the last XX hours

Creator Rank Followers Posts Engagements
@Quantumup1 X XXXXX X XXX

View More

Top assets mentioned In the posts about $orkas in the last XX hours

Johnson & Johnson (JNJ) Oruka Therapeutics, Inc. Common Stock (ORKA) AbbVie Inc (ABBV)

Top topics mentioned In the posts about $orkas in the last XX hours

$ucbjy, $jnj, $orka, $abbv, hc

Top Social Posts #


Top posts by engagements in the last XX hours

Showing only X posts for non-authenticated requests. Use your API key in requests for full results.

"H.C. Wainwright reit'd $ORKA Buy/$45 after Oruka📰that the FDA had cleared its IND application for its Phase 2a trial of ORKA-001 (the company's long-acting anti-IL-23p19 antibody) in moderate-to-severe PsO called EVERLAST-A. $ABBV $PTGX - $JNJ #EDAV25 H.C. Wainwright said in its note: "This program is a randomized double-blind placebo-controlled Phase 2a trial designed to evaluate the safety and efficacy of a single dose level of ORKA-001 in moderate-to-severe psoriasis patients. EVERLAST-A will enroll approximately XX patients randomized 3:1 to receive ORKA-001 or matching placebo. The"
@Quantumup1 on X 2025-07-23 18:20:33 UTC 3529 followers, 1203 engagements

"Stifel reiterated $ORKA Buy-$47 after $ORKA's disclosure of the IND clearance for ORKA-001 and then catching up w/ mgmt. $ABBV $PTGX $JNJ #EADV25 $UCBJY $MLTX Stifel said in its note: "We caught up with management who noted that the IND clearance was based on interim Ph1 data (safety/tolerability) and Ph2a sites are open and actively enrolling -- Ph1 results to be presented at #EADV in September. Recall ORKA-001 is a next-gen IL-23p19 which is designed to explore greater exposure and improved dosing vs. mega-blockbuster Skyrizi based on exploratory IST results in Psoriasis demonstrating"
@Quantumup1 on X 2025-07-21 13:12:41 UTC 3530 followers, 4206 engagements

$orkas
/topic/$orkas